clearly illustrated by the redundancy in organizational structure of the stress response systems in the CNS and the skin (8, 13). This redundancy has its functional consequences when psychological stress–mediated activation of central HPA axis signaling negatively affects protective and antimicrobial skin barrier function, as is demonstrated in this issue by Aberg et al. (7). These findings will hopefully have clinical impact by stimulating the development of systemic and topical selective receptor antagonists for peptide and steroidoidal messengers of the HPA axis, as well as topical use of stimulators of cortisol metabolic inactivation, and the use of inhibitors of steroidogenesis in order to improve the antimicrobial and protective barrier activity of the skin. This may also be the dawn of a new clinical approach for the treatment of psychological stress–induced inflammatory dermatoses via the use of systemic or topical CRF1 antagonists.

Acknowledgments

Comments from Jacobo Wortsman and Curtis Dohan as well as NIH support (grant AR052190) are acknowledged.

Address correspondence to: Andrzej Slo-minski, Department of Pathology and Laboratory Medicine, Health Science Center, University of Tennessee, 930 Madison Avenue, Memphis, Tennessee 38163, USA. Phone: (901) 448-3741; Fax: (901) 448-6979; E-mail: aslominski@utmem.edu.


The effective T cell response to a tumor antigen requires not only stimulation by

Nonstandard abbreviations used: α-GalCer, α-galactosylceramide; OX40L, OX40 ligand; OX40L-DC, OX40L–transduced DC.

Conflict of interest: The author has declared that no conflict of interest exists.

Citation for this article: J. Clin. Invest. 117:3169–3172 (2007). doi:10.1172/JCI33976.

OX40 signaling directly triggers the antitumor effects of NKT cells

Dapeng Zhou

Department of Melanoma Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Pathways involving the costimulatory molecule OX40 and OX40 ligand (OX40L) enhance tumor rejection. It was presumed that this effect was mediated by changes in DCs and/or T cells. In this issue of the JCI, Zaini et al. report that, in mice, intratumoral injection of DCs genetically modified to express OX40L suppressed the growth of a preexisting melanoma by directly triggering an antitumor NKT cell response (see the related article beginning on page 3330). This work suggests that the intratumoral NKT cell population may be harnessed for cancer immunotherapy and that OX40 costimulation may be used as a unique trigger of the antitumor activity of these cells.

The effective T cell response to a tumor antigen requires not only stimulation by

activated T cells for completion of their differentiation programs and exertion of their antitumor functions such as the release of cytokines and cytotoxic granules. The TNF receptor family of costimulatory molecules continues to be of interest in an effort to identify candidate targets for the development of immunotherapeutics. Activation of many of these signaling pathways has caused tumor rejection in preclinical and clinical studies (2).

OX40 and OX40 ligand in antitumor immunity

The OX40 costimulatory molecule is a member of the TNF receptor family and is expressed on activated CD4+ T cells and CD8+ T cells (1). OX40 ligand (OX40L) belongs to the TNF superfamily and is
expressed on activated professional antigen-presenting cells such as DCs, macrophages, and B cells. The requirement of OX40 and OX40L in adaptive immune responses, especially in CD4 memory responses, is well established and has been reviewed elsewhere (1). OX40 signaling has been suggested to sustain the signaling pathways of the TCR, CD28, and the IL-2 receptor.

Manipulation of OX40 signaling has been shown to be an efficient approach to enhance antitumor immunity in several preclinical studies (3–5). These therapies include adoptive transfer of tumor-specific CD8+ T cells followed by vaccine therapy (3), combined therapy with an OX40 agonist and other costimulatory agents, and use of an OX40 agonist as an adjuvant for whole-tumor cell vaccines (5). The mechanism of action of OX40 in these different tumor systems is quite possibly variable. Expression of OX40 by CD4+ and/or CD8+ T cells is essential for OX40 agonists to exert their effect (3–5). DCs, the professional antigen-presenting cells that present tumor antigens, are the critical cellular component required to activate T cells. The role of OX40 in crosstalk between DCs and CD4+ and/or CD8+ T cells in tumor growth is only partially understood. Clearly, the TCR stimulation signal from DCs is the first signal required. It is also very clear that OX40 agonists provided critical signals after initial TCR stimulation. However, many questions remain: What are the exact molecular mechanisms leading to the functional changes of both DCs and T cells? What are the roles of other costimulatory molecules expressed by DCs? Do other immune cells such as macrophages, plasmacytoid DCs, NK cells, and NKT cells play a role in the crosstalk between DCs and T cells?

**NKT cells make a major difference**

In this issue of the *JCI*, Zaini et al. report a critical role for NKT cells in the therapeutic effect of OX40 in mice bearing a preexisting tumor (6). The authors developed a cell therapy method using bone marrow–derived DCs that were genetically engineered to overexpress OX40L through a recombinant adenoaviral-transducing approach. The majority of OX40L–transduced DCs (OX40L–DCs) expressed a 10-fold higher amount of OX40L protein on the cell surface. The function of the OX40L gene in the adenoavirally transduced DCs was verified by an immunization challenge experiment. Vaccinating mice by OX40L–DC–pulsed protein vaccine generated protective T cell immunity in a tumor prevention model. In order to locate the OX40 interaction to the tumor microenvironment, the authors used an intratumoral injection approach to treat mice carrying preexisting solid tumors. Excitingly, the intratumoral OX40L–DC cell therapy caused the rejection of established tumors, including a most aggressive, poorly immunogenic B16F10 melanoma. The therapeutic effects were strictly dependent on OX40 expression in the tumor-bearing mice, because OX40–/– mice failed to reject the tumor. Not surprisingly, both CD4+ and CD8+ T cells were also required.

A major finding reported by Zaini et al. (6) is that NKT cells are essential for the success of the OX40L–DC intratumoral therapy. OX40L–DCs failed to treat tumors in mice lacking NKT cells, and this report very nicely demonstrates the involvement of NKT cells by both gain-of-function and loss-of-function experiments.

Analysis of the lymphocyte population infiltrating the tumors in these animals indicated that 20% of the OX40-expressing cells were NKT cells (6). To estimate the function of these NKT cells, Zaini et al. used an intracellular staining technology to measure the cytokines they produce. IFN-γ was produced by 73% of the intratumoral NKT cells. Furthermore, a significant increase in IFN-γ was found in the tumor lysates. IFN-γ is a cytokine with well-established, potent antitumor functions, including sensitization of tumor cells for CD8+ T cell cytotoxicity and induction of angiostatic chemokines (7). Consistent with these findings, a 3-fold increase in intratumoral infiltration of CD4+ and CD8+ T cells was observed, suggesting increased production of intratumoral chemokines that may attract T cells. Future systemic studies on other immune cells and cytokine/chemokines in the tumor microenvironment might complete our understanding of these OX40L–DC–elicited responses. Of note, in human patients, positive associations between NKT cell presence in primary tumors and long-term survival have been demonstrated for distinct cancers (8). It might be interesting to study whether OX40L is associated with the presence of NKT cells.

**DC–NKT cell crosstalk and the role of OX40**

Invariant NKT cells represent a very special subset of innate lymphocytes that express markers of both NK cells and T cells. They express a very restricted repertoire of TCRs (Vα14 in mice and Vα24 in humans). In contrast to conventional T cells, which recognize peptide antigens presented by MHC molecules, NKT cells recognize glycolipid antigens presented by the nonpolymorphic, non-MHC antigen-presenting molecule CD1d (Figure 1). The activation of conventional T cells requires more than 12 hours of antigen stimulation, while NKT cells can be activated within 2 hours, a mechanism more similar to NK cells. The antitumor effect of invariant NKT cells was first discovered via mechanistic studies of the effects of the NKT cell stimulant α-galactosylceramide (α-GaICer), a marine sponge-derived glycosphingolipid that prevents metastasis of intravenously injected B16 melanoma cells in mice (9). The antitumor effect of NKT cells in established solid tumors is an area of research in which several central questions currently remain unanswered, such as: What is the life cycle of intratumoral NKT cells? What antigenic stimulation and costimulatory signals control the fate of NKT cells? What elements of the immune response (cellular or secreted factors) are involved in NKT cell–induced immune responses, and how? DC–NKT cell interaction is the starting point for us to find answers for these questions.

In this OX40L–DC intratumoral therapy model (6), it is a challenging task to study the crosstalk between DCs and NKT cells. Ideally, experimental systems should be designed to reproduce a scenario similar to the intratumoral interaction between OX40L–DCs and NKT cells. However, technically, this is extremely difficult because the tumor microenvironment contains multiple cellular components (tumor cells, granulocytes, DCs, macrophages, NK cells, CD4+ T cells, CD8+ T cells, and other cell types) as well as extremely diverse profiles of cytokines/chemokines produced by these cells. Simply mixing the OX40L–DCs with fresh NKT cells may not work. In view of this, Zaini et al. studied OX40 signaling by stimulating NKT cells with a potent agonist NKT antigen, α-GaICer. Both in vivo and in vitro experiments indicated that enhanced IFN-γ production is an outcome of OX40 signaling in NKT cells. As expected, in all experiments, NKT cell activation was strictly dependent on TCR stimulation, because the production of
IFN-γ by splenocytes could be completely blocked by anti-CD1d antibody, which blocks the TCR recognition of α-GalCer presented by CD1d.

An interesting point in the intratumoral DC–NKT cell interaction system described by Zaini et al. (6) is that the antigens that stimulate NKT cells are endogenous glycolipids presented by DCs, not foreign glycolipids such as α-GalCer. It is generally accepted that endogenous, self-glycolipid antigens for NKT cells are weaker antigens compared with α-GalCer. As a super agonist antigen, α-GalCer might provide stronger TCR signaling, which may partially bypass the costimulatory pathways that are required by the natural endogenous glycolipid ligands. Thus, in the scenario of TCR stimulation by endogenous ligands, there may be much more dependence on OX40 costimulation, and the defect of NKT cell function observed in OX40−−/− mice may be more severe.

**OX40 as a molecular switch at both priming and effector phases**

The antitumor immune response is a multistep process consisting of 2 phases. The first, the antigen-priming phase, involves the processing and presentation of tumor-associated antigens by antigen-presenting cells and the activation and proliferation of antigen-specific T cells. In the second phase, known as the effector phase, activated immune cells travel to the tumor site and exert their effector functions, which include cytokine production.

The critical role of DC–NKT cell crosstalk in the antigen-priming phase to generate tumor-specific T cells was previously reported by Fuji et al. using α-GalCer as the NKT stimulant (10) and demonstrated by the immunization challenge experiments of Zaini et al. using OX40 agonists (6). The mechanisms by which NKTs interact with OX40L-DCs in order to enhance the capacity of DCs to activate CD4+ and
CD8+ T cells remain unclear. The activation of DCs may involve a positive feedback loop consisting of IL-12 (secreted by DCs) and the IL-12 receptor (expressed by activated NKTs; Figure 1). Activated DCs stimulate CD4+ and CD8+ T cells through enhanced antigen presentation and expression of costimulatory molecules such as CD80, CD86, and CD40. To present tumor antigens to CD8+ T cells, a “cross-priming” process is required for the endocytosed tumor antigens to enter the cytosol of DCs before being processed by the proteasome and loaded in the endoplasmic reticulum. NKT cells might enhance the cross-priming process via the secretion of perforin, granzymes, or some as yet unknown molecular components into DCs, and cause the endocytosed tumor antigens to detach to the cytoplasm. Besides cells of the adaptive immune system, innate immune cells might also be critical for mediating the effects of the OX40L-DC treatment. In view of the potent production of IFN-γ and perforin by NK cells caused by NKT cell activation, the OX40L-DC treatment may be NK cell dependent.

It should be highlighted that in the effector phase of antitumor immunity, NKT cells, CD4+ and CD8+ T cells, and NK cells congregate to kill tumor cells, and crosstalk between these multiple cells may be essential for tumor rejection. OX40 expression by CD4+ and CD8+ T cells has been shown to be critical for cooperation between these two major cellular elements (3, 11). OX40 expression enhances the differentiation of CD8+ T cells (12, 13). OX40 expression on CD4+ T cells, and the presence of an OX40 agonist, control the proliferation and function of CD8+ T cells (3, 11). Interestingly, activated NK cells express OX40L, which might initiate crosstalk between NK cells and CD4+ T cells (14).

The OX40L-DC–stimulated NKT cells may alter the tumor microenvironment, rendering it favorable for CD8+ T cell– and NK cell–mediated cytotoxicity. These NKT cells may also lead to a quantitative and/or qualitative reduction in the numbers of immune suppressive cells such as CD4+Foxp3+ Tregs. The local NKT activation, local inflammation, and local infiltration of lymphocytes (CD4+ and CD8+ T cells as well as NK cells) may be required for the effects of this OX40L-DC therapy. In future studies, it would be interesting to ask whether this approach could be applied to treat metastatic disease. Specifically, is a systemic response elicited, or is the response limited to the tumor into which the DCs are injected?

**New therapeutics for NKT cell–based cancer therapy**

In the clinic, disseminated disease may render intratumoral injection of OX40L-DCs to every tumor site impossible. Targeted delivery of immune activators such as OX40 agonists may represent a promising direction for new drug development. This approach is not without clinical precedent. Bifunctional conjugates of immune activators and tumor-binding antibodies, such as the anti–CD2-mAb–IL-2 fusion protein (15), have shown success in curing solid tumors in preclinical studies and already passed phase I clinical trials, proven to be safe and immunologically active. The efficacy of these drugs to cause objective responses of human cancer are being evaluated in phase II trials.

A new trend in both translational and clinical research is to combine immune activators that stimulate different cellular subsets, with the goal being to obtain synergistic effects and enhanced antitumor efficacy. Teng et al. recently published the “NKTMab” therapy method involving combined treatment with αGalCer and mAbs (16). Combination of these agents and approaches might be considered when designing new clinical trials.

Combination of immune activators and chemotherapeutics may also offer a mechanism to enhance the efficacy of either modality alone. Activating the adaptive immune system via tumor-specific antigens, immunotherapy might provide a layer of specificity and minimize the inherent toxicity of currently employed chemotherapy drugs. NKT cells may provide an ideal target for these combined approaches. They possess a unique role in bridging innate and adaptive immunity, they demonstrate potent activation of DCs, and their agonists have a large therapeutic window. These properties may allow this enigmatic lymphocyte population to be harnessed in cancer therapy.

**Acknowledgments**

I thank Alexander Gelbard, Chen Dong, Xin Lin, Patrick Hwu, and Yong-Jun Liu for their help and advice.

**Address correspondence to:** Dapeng Zhou, Department of Melanoma Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA. Phone: (713) 792-3134; Fax: (713) 563-3424; E-mail: dzhou@mdanderson.org.